- AuthorisedPhase I and Phase II (Integrated)- First administration to humans
A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
This study is testing a new medicine, TOL2, for generalised myasthenia gravis. It's looking at how safe the medicine is, how well people can tolerate it, and if it affects the body's immune system. This is an early-stage UK trial.
For: generalised myasthenia gravisGermany · Denmark · Sweden - Ongoing, recruitingTherapeutic use (Phase IV)
An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)
This study looks at ways to help a medicine called Asfotase Alfa (STRENSIQ®) work better for people with Hypophosphatasia. Sometimes the body fights this medicine, so the study tests other treatments to stop that and improve how well the medicine works.
For: HYPOPHOSPHATASIAFrance - AuthorisedTherapeutic exploratory (Phase II)
Pulse corticosteroids or/and Immunoglobulins to treat fulminant Myocarditis: a double-blind randomized controlled adaptive trial (The CORIUM study)
This study looks at new ways to treat a serious heart condition called fulminant myocarditis. Researchers are testing if special medications, corticosteroids and immunoglobulins, can help patients recover better and quicker, focusing on improving heart function and survival.
For: Fulminant myocarditisFrance